Neuland Laboratories opened higher at ₹20,730.00, compared with its previous close of ₹20,565.00. During today's session, the stock has traded between ₹19,800.00 and ₹20,730.00, with an average traded price of ₹20,119.39. It is currently showing a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Neuland Laboratories is now worth
₹ 1,23,099.00
giving a profit of
₹ 1,13,099.00 (1130.99%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-205.00 (-1.00%)
Day High
₹20,730.00
Day Low
₹19,800.00
Day Open
₹20,730.00
Prev Close
₹20,565.00
Volume
76,650
Value Traded
₹154.22 Cr
1W Return
-6.93%
1M Return
-13.49%
3M Return
4.38%
6M Return
36.18%
1Y Return
24.79%
Market Cap (₹ Cr.)
26,122
PE Ratio
53.00
PB Ratio
14.09
Dividend Yield
0.17%
ROE
19.42%
ROCE
23.11%
Book Value (₹)
1,460.31
Face Value (₹)
10.00
EPS (TTM)
115.10
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-6.93%
6 Week
-
1 Month
-13.49%
3 Month
4.38%
9 Month
38.46%
Neuland Laboratories shares see ₹52.94 crore block trade on BSE
Confirmed block deal of ₹52.94 crore executed on BSE. Transaction involved 24,624 shares at ₹21,500 per share. Follows earlier real-time signal of ₹36.35 crore on NSE. Block deal size exceeds the ₹25 crore minimum threshold.
14 days agoNeuland Laboratories to host analysts at Goldman Sachs CDMO day
Neuland Laboratories to attend Goldman Sachs Global Healthcare CDMO Day. Event scheduled for September 23-25, 2026 in Singapore. Management to hold group and one-on-one investor meetings. Disclosure made under SEBI Regulation 30 on September 16, 2026.
27 days agoNeuland Laboratories to host analyst and investor meeting on September 23
Neuland Laboratories has scheduled a meeting with analysts and investors on September 23. The announcement was made by the company to inform stakeholders of the upcoming engagement.
27 days agoNeuland Laboratories Co-MD targets decade-long pharma and biotech partnerships
Neuland Laboratories' Co-MD is focused on strengthening partnerships with top pharma and biotech firms. The strategic objective is to meet customer needs over the next decade. The initiative reflects a long-term orientation toward deepening ties within the global pharmaceutical supply chain.
28 days agoNeuland starts first commercial peptide manufacturing module
Neuland commences operations of first commercial peptide module with 7,000 L total reactor capacity. Module one includes 750 L SPPS and 6,250 L LPPS capacity following a $30 million investment. Module two planned with up to 18,000 L capacity, starting ahead of schedule pending customer finalisation. Recent quarterly revenues rose 116% YoY driven by increased commercial and clinical projects.
28 days agoNeuland Laboratories schedules analyst meetings in Hyderabad
Neuland Laboratories schedules group investor meetings on September 15 and 17, 2026. Events include Emkay Global Investors Meeting and ICICI Securities Healthcare Day. Both meetings will be held in Hyderabad. Schedule is subject to change per SEBI Regulation 30 disclosure.
1mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 5 years ago in Neuland Laboratories is now worth
₹ 1,23,099.00
giving a profit of
₹ 1,13,099.00 (1130.99%)
Note: Past profits do not guarantee future returns.
